RxDoctor Payments Data

Lakshmi Pathak, MD

Nephrology · Fargo, NDNPI 1467616128

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $779 of the $1,047 with a category attached, or 74.4%. It is spread thinly across 21 manufacturers, the largest accounting for just 21.6%.

$1,047in general payments, 2019–2025

Across 29 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$226
  • AstraZeneca$114
  • GSK$106
  • Mallinckrodt Enterprises LLC$99
  • Bard Peripheral Vascular, Inc.$92
  • Cormedix Inc.$70
  • plus $340 from 15 others

What the payments were for

  • Food & beverage$77974%
  • Education$26826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047 in reported general payments places this provider in the 85th percentile of 22 nephrology providers in North Dakota.

See all nephrology providers in North Dakota

Medicare billing

Part B allowed, 2024
$259,372
Medicare patients
670
Services billed
2,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin11$86,462
FarxigaDapagliflozin Propanediol52$40,375
JardianceEmpagliflozin31$34,469
Sevelamer Carbonate35$6,811
Calcitriol372$6,546
Potassium Citrate ErPotassium Citrate34$4,240
Calcium Acetate38$3,521
Potassium Chloride27$2,873
Bumetanide70$2,168
Losartan Potassium118$1,246
Metoprolol Succinate61$1,201
Allopurinol105$1,015
LoperamideLoperamide Hcl15$894
Furosemide143$882
Amlodipine Besylate139$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$114$40,37552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 22 nephrology providers in North Dakota.

Other nephrology in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →